BiomX

108 articles about BiomX

• BiomX Announces the Appointment of Susan Blum to its Board of Directors

  4/18/2024

  BiomX Inc. today announced the appointment of Susan Blum to its Board of Directors.

• BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure

  4/4/2024

  BiomX Inc. announced that, as previously disclosed in its annual report on Form 10-K for the fiscal year ended December 31, 2023, which was filed with the Securities and Exchange Commission on April 4, 2024, the audit opinion contained a going concern qualification from the Company's independent registered public accounting firm.

• BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

  4/3/2024

  BiomX Inc. reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.

• BiomX to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on April 3rd, 2024

  3/27/2024

  BiomX Inc. announced that the Company will host a conference call and a live audio webcast on Wednesday, April 3rd, 2024, at 8:00 a.m. ET, to report fourth quarter and full year 2023 financial results and a provide business update.

• BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing

  3/18/2024

  BiomX Inc. announced the closing of its previously announced acquisition of Adaptive Phage Therapeutics, Inc. and its previously announced $50 million private placement to certain institutional accredited investors, which was led by affiliates of Deerfield Management Company and the AMR Action Fund, and additional investors including the Cystic Fibrosis Foundation, OrbiMed and Nantahala Capital.

• BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing

  3/6/2024

  BiomX Inc. today announced that it has entered into a definitive merger agreement with Adaptive Phage Therapeutics, Inc. (“APT”), a U.S.-based privately-held, clinical-stage biotechnology company pioneering the development of phage-based therapies to combat bacterial infections (the “Acquisition”).

• BiomX Receives Orphan Drug Designation from the U.S. Food and Drug Administration for BX004 for the Treatment of Chronic Pulmonary Infection Caused by Pseudomonas aeruginosa in Patients with Cystic Fibrosis

  1/4/2024

  BiomX Inc. today announced that its phage cocktail, BX004, has been granted Orphan Drug Designation (“ODD”) by the United States Food and Drug Administration (“FDA”).

• BiomX to Host Virtual Key Opinion Leader (KOL) Event to Review the Positive Results from Part 2 of Phase 1b/2a Trial of BX004 in Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Infections on December 4, 2023

  11/30/2023

  BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced it will host a virtual KOL Event on December 4, 2023 at 12:00 PM ET to discuss the positive topline results recently announced from Part 2 of Phase 1b/2a trial of BX004 in cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa (P. aeruginosa) infections.

• BiomX Announces Positive Topline Results from Part 2 of the Phase 1b/2a Trial Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis

  11/29/2023

  BiomX Inc. today announced positive safety and efficacy results from Part 2 of the Phase 1b/2a trial evaluating the Company’s novel phage cocktail, BX004, for the treatment of chronic pulmonary infections caused by Pseudomonas aeruginosa (or P. aeruginosa) in patients with cystic fibrosis (“CF”).

• BiomX Reports Third Quarter 2023 Financial Results and Provides Business Update

  11/14/2023

  BiomX Inc. reported financial results and provided a business update for the third quarter ended September 30, 2023.

• BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the 37th Annual North American Cystic Fibrosis Conference

  10/27/2023

  BiomX Inc. announced that the Company will present data from Part 1 of its ongoing Phase 1b/2a study evaluating the novel phage product candidate, BX004, for the treatment of chronic Pseudomonas aeruginosa pulmonary infections in people with cystic fibrosis at the 37th Annual North American Cystic Fibrosis Conference, which is being held November 2-4, 2023, in Phoenix, Arizona.

• BiomX Announces the Appointment of Edward L. Williams to its Board of Directors

  10/18/2023

  BiomX Inc., a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announced the appointment of Edward L. Williams to its Board of Directors.

• BiomX Announces Completion of Patient Dosing in Part 2 of the Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis

  10/4/2023

  BiomX Inc. announced the completion of patient dosing in Part 2 of the Phase 1b/2a trial evaluating the Company’s novel phage cocktail, BX004, for the treatment of chronic pulmonary infections caused by Pseudomonas aeruginosa in patients with cystic fibrosis.

• BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections

  9/7/2023

  BiomX Inc. today announced that the Company will present data from Part 1 of its ongoing Phase 1b/2a study evaluating the novel phage product candidate, BX004, for the treatment of chronic Pseudomonas a eruginosa.

• BiomX to Present at H.C. Wainwright 25th Annual Global Investment Conference

  9/6/2023

  BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that Jonathan Solomon, Chief Executive Officer of BiomX, will be presenting at the H.C. Wainwright 25th Annual Global Investment Conference.

• BiomX Reports Second Quarter 2023 Financial Results and Provides Business Update

  8/9/2023

  BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results and provided a business update for the second quarter ended June 30, 2023.

• BiomX to Host Second Quarter 2023 Financial Results Conference Call and Webcast on August 9th, 2023

  8/2/2023

  BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”) today announced that the Company will host a conference call and a live audio webcast on Wednesday, August 9th, 2023, at 8:00 a.m. ET, to report second quarter 2023 financial results and provide business updates.

• NYSE American Initiates Delisting Proceedings for BiomX Warrants Shares of the Company’s common stock and units (PHGE and PHGE.U) are unaffected by delisting proceedings of warrants and will remain trading on NYSE American

  6/8/2023

  BiomX Inc., a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announced that the Company’s warrants, which have been listed on NYSE American under the ticker symbol, PHGE.WS, are in the process of being delisted.

• BiomX to Present Part 1 Data from Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis During Late-Breaking Science Session at the 46th ECFC

  5/31/2023

  BiomX Inc. announced that the Company will present Part 1 data from its ongoing Phase 1b/2a study evaluating the novel phage product candidate, BX004, for the treatment of chronic Pseudomonas aeruginosa pulmonary infections in patients with cystic fibrosis during the Late-Breaking Science Session at 46th European Cystic Fibrosis Conference, which is being held June 7-10th, 2023, in Vienna, Austria.

• BiomX Reports First Quarter 2023 Financial Results and Provides Business Update

  5/15/2023

  BiomX Inc., a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, reported financial results and provided a business update for the first quarter ended March 31, 2023.